CN116710439A - 取代的吡唑并哌啶羧酸 - Google Patents

取代的吡唑并哌啶羧酸 Download PDF

Info

Publication number
CN116710439A
CN116710439A CN202180081892.0A CN202180081892A CN116710439A CN 116710439 A CN116710439 A CN 116710439A CN 202180081892 A CN202180081892 A CN 202180081892A CN 116710439 A CN116710439 A CN 116710439A
Authority
CN
China
Prior art keywords
compounds
diseases
compound
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180081892.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·瓦卡洛波洛斯
M-P·科兰-克勒佩兰
N·奥特加埃南德斯
A·迪斯考
M·布塔达基斯-阿拉皮尼斯
L·坎迪什
T·施泰尔费尔德
I·马萨
L·H·霍夫梅斯特
P·桑德纳
F·文德
L·迪茨
R·A·韦伯斯特
C·施迈克
T·蒙德利茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of CN116710439A publication Critical patent/CN116710439A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180081892.0A 2020-12-10 2021-12-09 取代的吡唑并哌啶羧酸 Pending CN116710439A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20213020.9 2020-12-10
EP20213020 2020-12-10
PCT/EP2021/084987 WO2022122914A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (1)

Publication Number Publication Date
CN116710439A true CN116710439A (zh) 2023-09-05

Family

ID=73793025

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180081892.0A Pending CN116710439A (zh) 2020-12-10 2021-12-09 取代的吡唑并哌啶羧酸

Country Status (31)

Country Link
US (1) US20240051935A1 (https=)
EP (1) EP4259617B1 (https=)
JP (1) JP2023552583A (https=)
KR (1) KR20230118144A (https=)
CN (1) CN116710439A (https=)
AR (1) AR124297A1 (https=)
AU (1) AU2021393988A1 (https=)
CA (1) CA3204495A1 (https=)
CL (1) CL2023001632A1 (https=)
CO (1) CO2023007335A2 (https=)
CR (1) CR20230242A (https=)
DK (1) DK4259617T3 (https=)
DO (1) DOP2023000115A (https=)
EC (1) ECSP23040828A (https=)
ES (1) ES2997117T3 (https=)
FI (1) FI4259617T3 (https=)
GE (2) GEAP202316287A (https=)
HR (1) HRP20241543T1 (https=)
HU (1) HUE069255T2 (https=)
IL (1) IL303296A (https=)
JO (1) JOP20230132A1 (https=)
LT (1) LT4259617T (https=)
MX (1) MX2023006903A (https=)
PE (1) PE20231501A1 (https=)
PL (1) PL4259617T3 (https=)
PT (1) PT4259617T (https=)
RS (1) RS66294B1 (https=)
SA (1) SA523441083B1 (https=)
SI (1) SI4259617T1 (https=)
TW (1) TW202237589A (https=)
WO (1) WO2022122914A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067414A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用
WO2025162280A1 (zh) * 2024-01-30 2025-08-07 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
WO2024163561A1 (en) * 2023-01-31 2024-08-08 Invivosciences, Inc. Systems and methods for treating heart failure with preserved ejection fraction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032249A1 (en) * 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
WO2012058132A1 (en) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
UA109650C2 (xx) 2010-02-27 2015-09-25 Біс-арилзв'язані арилтриазолони та їх застосування
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
HRP20191755T1 (hr) * 2012-09-07 2019-12-27 Boehringer Ingelheim International Gmbh Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
SI3215498T1 (sl) 2014-11-03 2018-11-30 Bayer Pharma Aktiengesellschaft Hidroksialkil-substituirani derivati feniltriazola in njihove uporabe
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CN116829545A (zh) * 2020-12-10 2023-09-29 拜耳公司 取代的吡唑基哌啶羧酸
AU2021398486A1 (en) * 2020-12-10 2023-06-22 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032249A1 (en) * 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
WO2012058132A1 (en) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025067414A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用
WO2025162280A1 (zh) * 2024-01-30 2025-08-07 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用

Also Published As

Publication number Publication date
DOP2023000115A (es) 2023-07-16
AU2021393988A1 (en) 2023-06-22
DK4259617T3 (da) 2024-12-09
CL2023001632A1 (es) 2023-11-10
LT4259617T (lt) 2024-12-10
PE20231501A1 (es) 2023-09-26
CA3204495A1 (en) 2022-06-16
GEAP202316287A (en) 2023-09-11
AU2021393988A9 (en) 2024-09-19
JP2023552583A (ja) 2023-12-18
PL4259617T3 (pl) 2025-03-17
GEP20247649B (en) 2024-07-25
SI4259617T1 (sl) 2025-02-28
AR124297A1 (es) 2023-03-15
HUE069255T2 (hu) 2025-02-28
EP4259617B1 (en) 2024-10-23
PT4259617T (pt) 2024-12-05
EP4259617A1 (en) 2023-10-18
ECSP23040828A (es) 2023-07-31
IL303296A (en) 2023-07-01
KR20230118144A (ko) 2023-08-10
SA523441083B1 (ar) 2025-06-12
US20240051935A1 (en) 2024-02-15
RS66294B1 (sr) 2025-01-31
HRP20241543T1 (hr) 2025-01-03
WO2022122914A1 (en) 2022-06-16
FI4259617T3 (fi) 2024-11-27
MX2023006903A (es) 2023-06-26
ES2997117T3 (en) 2025-02-14
CR20230242A (es) 2023-07-19
CO2023007335A2 (es) 2023-06-09
JOP20230132A1 (ar) 2023-06-08
TW202237589A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
CN114981257B (zh) 取代的吡唑并哌啶羧酸
CN116710439A (zh) 取代的吡唑并哌啶羧酸
EP4259616B1 (en) Substituted pyrazolo piperidine carboxylic acids
EP4259618A1 (en) Substituted pyrazolyl piperidine carboxylic acids
HK40091213A (zh) 取代的吡唑并哌啶羧酸
HK40118186A (zh) 取代的吡唑并哌啶羧酸
HK40073287A (en) Substituted pyrazolo piperidine carboxylic acids
HK40118187A (zh) 取代的吡唑并哌啶羧酸
HK40073287B (zh) 取代的吡唑并哌啶羧酸
EA047635B1 (ru) Замещенные пиразолопиперидинкарбоновые кислоты
EA049460B1 (ru) Замещенные пиразолопиперидинкарбоновые кислоты
BR122025013946A2 (pt) Ácidos carboxílicos de pirazolo piperidina substituídos, seus processos de preparação

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40091213

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: A. Vacaropoulos

Inventor after: Sandner Peter

Inventor after: F. Wende

Inventor after: L. Dietz

Inventor after: R.A. Webster

Inventor after: C. Schmike

Inventor after: T's medley

Inventor after: M.G. Hahn

Inventor after: M. Forman

Inventor after: J. Dreyer

Inventor after: A. Gromov

Inventor after: M-P. Colan-Klepeland

Inventor after: N. Ortega Hernandez

Inventor after: Dysko Adam

Inventor after: M. Butadakis Alapinis

Inventor after: L. Candish

Inventor after: stellfeld Timo

Inventor after: 1. Massa

Inventor after: L H Hofmeister

Inventor before: A. Vacaropoulos

Inventor before: Sandner Peter

Inventor before: F. Wende

Inventor before: L. Dietz

Inventor before: R.A. Webster

Inventor before: C. Schmike

Inventor before: T's medley

Inventor before: M-P. Colan-Klepeland

Inventor before: N. Ortega Hernandez

Inventor before: Dysko Adam

Inventor before: M. Butadakis Alapinis

Inventor before: L. Candish

Inventor before: stellfeld Timo

Inventor before: 1. Massa

Inventor before: L H Hofmeister